Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

Summary

This phase II trial studies how well trametinib works in increasing tumoral iodine incorporation in patients with thyroid cancer that has come back or spread to another place in the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help make treatment with iodine I-131 more effective.

Conditions

• Metastatic Thyroid Gland Carcinoma
• Poorly Differentiated Thyroid Gland Carcinoma
• Recurrent Thyroid Gland Carcinoma
• Refractory Thyroid Gland Carcinoma
• Stage IV Thyroid Gland Follicular Carcinoma AJCC v7
• Stage IV Thyroid Gland Papillary Carcinoma AJCC v7
• Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7
• Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7
• Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7
• Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7
• Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7
• Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7

Interventions

PROCEDURE

Computed Tomography

Undergo iodine I-124 PET/CT

OTHER

Iodine I 124

Undergo iodine I-124 PET/CT

RADIATION

Iodine I-131

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacodynamic Study

Correlative studies

PROCEDURE

Positron Emission Tomography

Undergo iodine I-124 PET/CT

DRUG

Trametinib

Given PO

Sponsors & Collaborators

• National Cancer Institute (NCI)

  lead NIH

Principal Investigators

• Alan L Ho · Memorial Sloan Kettering Cancer Center

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2014-08-14

Primary Completion

2021-08-25

Completion

2027-02-05

Countries

• United States

Study Locations